Основная статистика
| CIK | 1436304 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Kythera Biopharma
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* KYTHERA Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| February 8, 2016 |
KYTH / Kythera Biopharma / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 26, 2016 |
EX-99.1 2 d15947dex991.htm EX-99.1 CUSIP No. 501570 10 5 13G Exhibit A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of KYTHERA Biopharmaceuticals |
|
| January 26, 2016 |
SC 13G/A 1 d15947dsc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* KYTHERA Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 501570 10 5 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing of This Statement) Check t |
|
| October 13, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35663 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as spec |
|
| October 2, 2015 |
KYTH / Kythera Biopharma / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KYTHERA Biopharmaceuticals, Inc. (Amendment No. 1) (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 501570105 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Tele |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-184439 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-187538 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194735 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-198512 Post |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-184439 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-187538 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194735 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-198512 Post |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-184439 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-187538 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194735 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-198512 Post |
|
| October 1, 2015 |
EX-3.1 2 a15-205701ex3d1.htm EX-3.1 Exhibit 3.1 BYLAWS OF KYTHERA BIOPHARMACEUTICALS, INC. a Delaware Corporation (hereinafter referred to as the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and the registered agent of the Corporation are as set forth in the Certificate of Incorporation. Section 2. Other Offices. The Corporation may also have offices at such |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-198511 UNDER THE SECURITIES ACT OF 1933 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 03-0552903 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 309 |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-184439 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-187538 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194735 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-198512 Post |
|
| October 1, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-184439 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-187538 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-194735 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-198512 Post |
|
| October 1, 2015 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 1, 2015 KYTHERA BIOPHARMACEUTICALS, INC. |
|
| September 28, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 a15-2031518k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 28, 2015 (September 28, 2015) Date of Report (date of earliest event reported) KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-35663 03-0552903 |
|
| August 21, 2015 |
DEFM14A 1 a2225753zdefm14a.htm DEFM14A Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check |
|
| August 20, 2015 |
KYTH / Kythera Biopharma / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KYTHERA Biopharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 501570105 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Pe |
|
| August 18, 2015 |
Exhibit 99.1 KYTHERA? Biopharmaceuticals Submits Marketing Authorization Application in the European Union for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat Submission supported by four pivotal Phase III trials conducted in Europe and North America with more than 1,500 patients Westlake Village, Calif., U.S., August 18, 2015 - KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH |
|
| August 18, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 a15-1817718k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisd |
|
| August 10, 2015 |
KYTH / Kythera Biopharma / Allergan plc - SCHEDULE 13D (AMENDMENT NO. 2) Activist Investment Schedule 13D (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2)* Under the Securities Exchange Act of 1934 KYTHERA BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 501570105 (CUSIP Number) A. Robert D. Bailey Allergan plc Chief Legal Officer and Corporate Secretary Clonsha |
|
| August 6, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-1669318k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2015 KYTHERA Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdi |
|
| August 6, 2015 |
EX-10.1 2 kyth-20150630ex1015bd088.htm EX-10.1 Exhibit 10.1 KYTHERA BIOPHARMACEUTICALS, INC. EXECUTIVE CHANGE IN CONTROL AND SEPARATION BENEFITS PLAN (AND SUMMARY PLAN DESCRIPTION) EFFECTIVE MAY 26, 2015 This KYTHERA Biopharmaceuticals, Inc. Executive Change in Control and Separation Benefits Plan (this “Plan”) was established effective as of May 26, 2015 (the “Effective Date”). The purpose of thi |
|
| August 6, 2015 |
KYTH / Kythera Biopharma 10-Q - Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 6, 2015 |
EX-99.1 2 a15-166931ex99d1.htm EX-99.1 Exhibit 99.1 KYTHERA Biopharmaceuticals Releases Second Quarter 2015 Operating Results and Progress Update Company Executing on Commercial Launch of KYBELLA™ (deoxycholic acid) Injection Westlake Village, Calif., Aug. 6, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the second quarter of 2015, and provided an upda |
|
| August 5, 2015 |
EX-99.1 3 a2225617zex-991.htm EX-99.1 QuickLinks - Click here to rapidly navigate through this document Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Considerat |
|
| August 5, 2015 |
EX-2.1 2 a2225617zex-21.htm EX-2.1 Use these links to rapidly review the document TABLE OF CONTENTS Exhibit 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of August 4, 2015 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Se |
|
| August 5, 2015 |
Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration EX-99.1 4 d35780dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. – August 5, 2015 – A |
|
| August 5, 2015 |
Allergan + Kythera Frequently Asked Questions Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Allergan + Kythera Frequently Asked Questions This FAQ contains responses to common questions related to employ |
|
| August 5, 2015 |
AMENDED AND RESTATED STOCKHOLDER VOTING AGREEMENT EX-10.1 Exhibit 10.1 AMENDED AND RESTATED STOCKHOLDER VOTING AGREEMENT THIS AMENDED AND RESTATED STOCKHOLDER VOTING AGREEMENT, dated as of August 4, 2015 (as amended, modified or supplemented from time to time in accordance with its terms, this Agreement), is entered into by and between Allergan plc, a company incorporated under the laws of Ireland (Parent), and each of the individuals or enti |
|
| August 5, 2015 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K 1 a2225617z8-k.htm 8-K QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delawar |
|
| August 5, 2015 |
EX-2.1 2 a2225617zex-21.htm EX-2.1 Use these links to rapidly review the document TABLE OF CONTENTS Exhibit 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of August 4, 2015 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Se |
|
| August 5, 2015 |
EX-2.1 Exhibit 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of August 4, 2015 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 2 Section 1.1 The Merger 2 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 3 Section 1.5 Officers and Directors of the Surviving Corporati |
|
| August 5, 2015 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: Mark Marmur (862) 261-7558 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce that Pending Transaction will now be for All-Cash Consideration DUBLIN, IRELAND and WESTLAKE VILLA |
|
| August 5, 2015 |
QuickLinks - Click here to rapidly navigate through this document SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 4, 2015 KYTHERA BIOPHARMACEUTICALS, INC. |
|
| August 5, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 5, 2015 |
Allergan FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 4, 2015 ALLERGAN PLC (Exact name of registrant as specified in its charter) Ireland 001-36867 98-1114402 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 27, 2015 |
Allergan FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 27, 2015 ALLERGAN PLC (Exact name of registrant as specified in its charter) Ireland 001-36867 98-1114402 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 a15-1636618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 27, 2015 Date of Report (Date of Earliest Event Reported) KYTHERA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35663 03-0552903 (State or Other of Incorp |
|
| July 27, 2015 |
EX-99.1 2 a15-163661ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA DUBLIN, IRELAND and WEST |
|
| July 27, 2015 |
EX-99.1 2 d51188dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan’s Pending Acquisition of KYTHERA DUBLIN, IRELAND and WESTLAKE |
|
| July 27, 2015 |
Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan?s Pending Acquisition of KYTHERA DUBLIN, IRELAND and WESTLAKE VILLAGE, CALIF. ? July 27, 2015 ? |
|
| July 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 27, 2015 Date of Report (Date of Earliest Event Reported) KYTHERA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-35663 03-0552903 (State or Other of Incorporation) (Commission File N |
|
| July 7, 2015 |
Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Dear KYTHERA Colleagues, I want to share some important details regarding the pre-integration planning activiti |
|
| July 2, 2015 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF MERGER Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 (this ?Amendment?), dated as of July 1, 2015, to the Agreement and Plan of Merger (the ?Merger Agreement?), dated as of June 17, 2015, is by and among Allergan plc, a company incorporated under the laws of Ireland (formerly known as Actavis plc) (?Parent?), Keto Merger Sub, Inc., a Delaware corporation and an indirect |
|
| July 2, 2015 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2015 KYTHERA BIOPHARMACEUTICALS, INC. |
|
| July 2, 2015 |
Allergan FORM 8-K (Prospectus) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2015 ALLERGAN PLC (Exact name of registrant as specified in its charter) Ireland 001-36867 98-1114402 (State or other jurisdiction of incorporation) (Commission File |
|
| July 2, 2015 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF MERGER Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 (this ?Amendment?), dated as of July 1, 2015, to the Agreement and Plan of Merger (the ?Merger Agreement?), dated as of June 17, 2015, is by and among Allergan plc, a company incorporated under the laws of Ireland (formerly known as Actavis plc) (?Parent?), Keto Merger Sub, Inc., a Delaware corporation and an indirect |
|
| July 2, 2015 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2015 KYTHERA BIOPHARMACEUTICALS, INC. |
|
| July 2, 2015 |
AMENDMENT NO. 1 AGREEMENT AND PLAN OF MERGER EX-2.1 2 d78450dex21.htm EX-2.1 Exhibit 2.1 Execution Version AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER This AMENDMENT NO. 1 (this “Amendment”), dated as of July 1, 2015, to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of June 17, 2015, is by and among Allergan plc, a company incorporated under the laws of Ireland (formerly known as Actavis plc) (“Parent”), Keto Merger |
|
| July 2, 2015 |
KYTH / Kythera Biopharma / Allergan plc - SCHEDULE 13D (AMENDMENT NO. 1) Activist Investment Schedule 13D (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1)* Under the Securities Exchange Act of 1934 KYTHERA BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 501570105 (CUSIP Number) A. Robert D. Bailey Allergan plc Chief Legal Officer and Corporate Secretary 1 Grand |
|
| June 29, 2015 |
KYTH / Kythera Biopharma / Allergan plc - SCHEDULE 13D Activist Investment Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 KYTHERA BIOPHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.00001 par value (Title of Class of Securities) 501570105 (CUSIP Number) A. Robert D. Bailey Allergan plc Chief Legal Officer and Corporate Secretary 1 Grand Canal Square, Docklands Dublin 2, Ir |
|
| June 25, 2015 |
Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 The following memorandum was sent to employees of Kythera Biopharmaceuticals, Inc. on June 24, 2015: June 24, 2 |
|
| June 25, 2015 |
425 1 a15-140755425.htm 425 Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 The following memorandum was sent to employees of Kythera Biopharmaceuticals, Inc. |
|
| June 25, 2015 |
Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Dear Dr [Last Name]: We are looking forward to seeing you at the KYBELLA? Educational Congress (KEC) Product Tr |
|
| June 17, 2015 |
EX-2.1 2 d943390dex21.htm EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of June 17, 2015 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 2 Section 1.5 Officers and Directors of t |
|
| June 17, 2015 |
425 Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: Allergan plc Subject Company: KYTHERA Biopharmaceuticals, Inc. |
|
| June 17, 2015 |
425 Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: Allergan plc Subject Company: KYTHERA Biopharmaceuticals, Inc. |
|
| June 17, 2015 |
KYTHERA BIOPHARMACEUTICALS, INC. RETENTION PLAN Effective as of June 16, 2015 EX-10.1 3 a15-140751ex10d1.htm EX-10.1 Exhibit 10.1 KYTHERA BIOPHARMACEUTICALS, INC. RETENTION PLAN Effective as of June 16, 2015 1. Introduction and Purpose. This KYTHERA Biopharmaceuticals, Inc. Retention Plan (the “Plan”) has been adopted effective as of June 16, 2015 (the “Effective Date”) in connection with the transaction contemplated under that certain Agreement and Plan of Merger, dated Ju |
|
| June 17, 2015 |
425 Filing pursuant to Rule 425 under the Securities Act of 1933, as amended Deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Filer: Allergan plc Subject Company: KYTHERA Biopharmaceuticals, Inc. |
|
| June 17, 2015 |
EX-99.1 4 a15-140751ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan to Acquire KYTHERA Biopharmaceuticals — Complements Allergan’s Existing Position in Facial Aesthetics — — Lead Product KYBELLA™ the First and Onl |
|
| June 17, 2015 |
EX-2.1 2 a15-140751ex2d1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of June 17, 2015 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 2 Section 1.5 Officers and Directors of the Surviving Co |
|
| June 17, 2015 |
Allergan and KYTHERA Combine to Enhance Facial Aesthetics Industry-Leading Portfolio Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 The following letter to customers of Kythera Biopharmaceuticals, Inc. was sent on June 17, 2015: June 17,2015 A |
|
| June 17, 2015 |
425 1 a15-1407518k.htm 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 17, 2015 (June 16, 2015) KYTHERA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35663 03-0552903 (State or Other Jurisdiction |
|
| June 17, 2015 |
8-K 1 a15-1407518k.htm 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 17, 2015 (June 16, 2015) KYTHERA BIOPHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-35663 03-0552903 (State or Other Jurisdiction |
|
| June 17, 2015 |
Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 The following question and answer document was sent to employees of Kythera Biopharmaceuticals, Inc. on June 17 |
|
| June 17, 2015 |
EX-99.1 4 d943390dex991.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan to Acquire KYTHERA Biopharmaceuticals – Complements Allergan’s Existing Position in Facial Aesthetics – – Lead Product KYBELLA™ the First and Only A |
|
| June 17, 2015 |
KYTHERA BIOPHARMACEUTICALS, INC. RETENTION PLAN Effective as of June 16, 2015 Exhibit 10.1 KYTHERA BIOPHARMACEUTICALS, INC. RETENTION PLAN Effective as of June 16, 2015 1. Introduction and Purpose. This KYTHERA Biopharmaceuticals, Inc. Retention Plan (the ?Plan?) has been adopted effective as of June 16, 2015 (the ?Effective Date?) in connection with the transaction contemplated under that certain Agreement and Plan of Merger, dated June 17, 2015 (the ?Merger Agreement?), b |
|
| June 17, 2015 |
EX-2.1 2 a15-140751ex2d1.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among ALLERGAN PLC, KETO MERGER SUB, INC. and KYTHERA BIOPHARMACEUTICALS, INC. dated as of June 17, 2015 TABLE OF CONTENTS Page ARTICLE I. THE MERGER 1 Section 1.1 The Merger 1 Section 1.2 Closing 2 Section 1.3 Effective Time 2 Section 1.4 Governing Documents 2 Section 1.5 Officers and Directors of the Surviving Co |
|
| June 17, 2015 |
Filed by Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Kythera Biopharmaceuticals, Inc. Commission File No. 001-35663 The following memorandum was sent to employees of Kythera Biopharmaceuticals, Inc. on June 17, 2015: Allergan A |
|
| June 17, 2015 |
EX-99.1 4 a15-140751ex99d1.htm EX-99.1 Exhibit 99.1 NEWS RELEASE CONTACTS: Allergan: Investors: Lisa DeFrancesco (862) 261-7152 Media: David Belian (862) 261-8141 KYTHERA: Investors: Heather Rowe (818) 587-4559 Media: Ashley Cadle (310) 463-0143 Allergan to Acquire KYTHERA Biopharmaceuticals — Complements Allergan’s Existing Position in Facial Aesthetics — — Lead Product KYBELLA™ the First and Onl |
|
| June 17, 2015 |
EX-10.1 Exhibit 10.1 STOCKHOLDER VOTING AGREEMENT THIS STOCKHOLDER VOTING AGREEMENT, dated as of June 17, 2015 (this ?Agreement?), is entered into by and between Allergan plc, a company incorporated under the laws of Ireland (?Parent?), and each of the individuals or entities listed on the signature pages hereto (each, a ?Stockholder? and, together, the ?Stockholders?). RECITALS A. Concurrently wi |
|
| June 17, 2015 |
Allergan FORM 8-K (Prospectus) 425 1 d943390d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 17, 2015 ALLERGAN PLC (Exact name of registrant as specified in its charter) Ireland 001-36867 98-1114402 (State or other jurisdiction of incorporat |
|
| June 4, 2015 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Comm |
|
| June 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2015 KYTHERA Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Comm |
|
| May 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 7, 2015 |
Exhibit 99.1 KYTHERA Biopharmaceuticals Releases First Quarter 2015 Operating Results and Progress Update Company Well Positioned for Commercial Launch of KYBELLA? (deoxycholic acid) Injection Westlake Village, Calif., May 7, 2015 ? KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the first quarter of 2015, and provided an update on recent accomplishments. ?KYTH |
|
| May 7, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2015 KYTHERA Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Commi |
|
| May 4, 2015 |
Exhibit 99.1 KYTHERA Biopharmaceuticals Announces FDA Approval of KYBELLA? (also known as ATX-101) ? First and Only Submental Contouring Injectable Drug KYBELLA? (deoxycholic acid) Injection Significantly Improves Submental Fullnesss, or ?Double Chin? Westlake Village, Calif., April 29, 2015 ? KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) announced today that the U.S. Food and Drug Administratio |
|
| May 4, 2015 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| April 23, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 16, 2015 |
Exhibit 1.1 EXECUTION VERSION UNDERWRITING AGREEMENT KYTHERA Biopharmaceuticals, Inc. 2,604,168 Shares of Common Stock Underwriting Agreement March 10, 2015 Goldman, Sachs & Co. Merrill Lynch, Pierce, Fenner & Smith Incorporated Leerink Partners LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o Goldman, Sachs & Co. 200 West Street New York, NY 10282-2198 c/o Merril |
|
| March 16, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| March 11, 2015 |
Use these links to rapidly review the document Table of Contents Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| March 9, 2015 |
Use these links to rapidly review the document Table of Contents Table of Contents Filed pursuant to Rule 424(b)(5) Registration Statement No. |
|
| March 2, 2015 |
Exhibit 10.21 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. LICENSE AGREEMENT DATED AS OF FEBRUARY , 2015 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND KYTHERA HOLDINGS, LTD. AND KYTHERA BIOPHARMACEUTICALS, INC. CONFIDEN |
|
| March 2, 2015 |
Exhibit 10.20 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. CONFIDENTIAL INFORMATION EXECUTION COPY LICENSE AGREEMENT This license agreement (the “Agreement”) is effective as of February , 2015 (the “Effective Date”) by and among ACTELION P |
|
| March 2, 2015 |
List of Subsidiaries of KYTHERA Biopharmaceuticals, Inc. QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 List of Subsidiaries of KYTHERA Biopharmaceuticals, Inc. Jurisdiction of Incorporation or Organization Kythera Biopharmaceuticals (Europe) Ltd. United Kingdom Kythera Biopharmaceuticals Australia Pty. Ltd. Australia Kythera Holdings Ltd. Bermuda QuickLinks Exhibit 21.1 List of Subsidiaries of KYTHERA Biopharmaceuticals, |
|
| March 2, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Com |
|
| March 2, 2015 |
Second Amendment to Manufacturing and Supply Agreement Exhibit 10.8(c) Second Amendment to Manufacturing and Supply Agreement This Second Amendment to the Manufacturing and Supply Agreement (this ?Second Amendment?) is made as of October 17, 2014 (the ?Effective Date of this Second Amendment?) by and between Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware, with offices at 235 E. 42nd Street, New York, NY 1001 |
|
| March 2, 2015 |
KYTHERA Biopharmaceuticals Announces 2014 Operating Results Exhibit 99.1 KYTHERA Biopharmaceuticals Announces 2014 Operating Results Westlake Village, Calif., March 2, 2015 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its quarter and year ended December 31, 2014, and provided an update on recent accomplishments. “Last year KYTHERA achieved many milestones and this year we continue our upward momentum. Most notably, |
|
| March 2, 2015 |
DISTRIBUTION SERVICES AGREEMENT Exhibit 10.22 DISTRIBUTION SERVICES AGREEMENT This Distribution Services Agreement (?Agreement?) dated as of January 16, 2015 (?Effective Date?), is made by and between KYTHERA Biopharmaceuticals, Inc. (?Company?) and Besse Medical, a division of ASD Specialty Healthcare, Inc. (?Distributor?). RECITALS A. The Company is a manufacturer and supplier of biological therapeutic products including the p |
|
| March 2, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Use these links to rapidly review the document TABLE OF CONTENTS PART IV KYTHERA BIOPHARMACEUTICALS, INC. |
|
| February 13, 2015 |
Exhibit 99.1 KYTHERA BIOPHARMACEUTICALS, INC. 2015 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE, SCOPE AND ADMINISTRATION OF THE PLAN 1.1 Purpose and Scope. The purpose of the Kythera Biopharmaceuticals, Inc. 2015 Employee Stock Purchase Plan, as it may be amended from time to time, (the “Plan”) is to assist employees of Kythera Biopharmaceuticals, Inc., a Delaware corporation, (the “Company”) |
|
| February 13, 2015 |
Kythera Biopharmaceuticals, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No. 1* Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 13, 2015 |
KYTH / Kythera Biopharma S-8 - - S-8 As filed with the Securities and Exchange Commission on February 13, 2015 Registration No. |
|
| February 13, 2015 |
Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 |
|
| February 13, 2015 |
Joint Filing Agreement EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc. |
|
| February 13, 2015 |
Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc. |
|
| February 13, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| February 11, 2015 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) ( |
|
| February 11, 2015 |
KYTH / Kythera Biopharma / ARCH VENTURE FUND VI LP - KYTHERA BIOPHARMACEUTICALS Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KYTHERA Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w |
|
| January 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2015 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) ( |
|
| January 27, 2015 |
KYTH / Kythera Biopharma / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 6, 2015 |
Exhibit 99.1 KYTHERA Biopharmaceuticals Appoints Hollings C. Renton to Board of Directors Former Onyx CEO Brings Additional Company Building Experience to KYTHERA Board Westlake Village, Calif., January 5, 2015 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that it has named Hollings C. Renton to its Board of Directors. Mr. Renton brings extensive biotechnology leadership experi |
|
| January 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| November 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 10, 2014 |
Exhibit 99.1 PRESS RELEASE KYTHERA Biopharmaceuticals Releases Third Quarter 2014 Operating Results Westlake Village, Calif., November 10, 2014 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its third quarter 2014 and provided an update on recent accomplishments. “We’ve demonstrated good progress in advancing our ATX-101 program. Of note, we continue to incr |
|
| November 10, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2014 KYTHERA Biopharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| November 6, 2014 |
KYTH / Kythera Biopharma S-3/A - - S-3/A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on November 6, 2014 Registration No. |
|
| November 5, 2014 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) ( |
|
| November 5, 2014 |
TERMINATION AND WAIVER AGREEMENT Exhibit 10.1 TERMINATION AND WAIVER AGREEMENT This Termination and Waiver Agreement (this “Agreement”) is dated as of November 5, 2014, by and among KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), KYTHERA Holdings Ltd., a company incorporated under the laws of Bermuda (“KHL”) (solely for purposes of Article II hereof), and Bayer Consumer Care AG, a company organized under |
|
| September 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| September 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No.1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No.1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: |
|
| September 17, 2014 |
KYTH / Kythera Biopharma CORRESP - - KYTHERA Biopharmaceuticals, Inc. 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 September 17, 2014 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Joel Parker, Accounting Branch Chief Vanessa Robertson, Staff Accountant Re: KYTHERA |
|
| September 2, 2014 |
KYTH / Kythera Biopharma S-8 - - S-8 As filed with the Securities and Exchange Commission on September 2, 2014 Registration No. |
|
| September 2, 2014 |
KYTHERA BIOPHARMACEUTICALS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN ARTICLE 1. Exhibit 99.1 KYTHERA BIOPHARMACEUTICALS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN ARTICLE 1. PURPOSE The purpose of the Kythera Biopharmaceuticals, Inc. 2014 Employment Commencement Incentive Plan (the “Plan”) is to promote the success and enhance the value of Kythera Biopharmaceuticals, Inc. (the “Company”) by linking the individual interests of the Eligible Participants to those of the C |
|
| September 2, 2014 |
Exhibit 99.3 KYTHERA BIOPHARMACEUTICALS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Kythera Biopharmaceuticals, Inc., a Delaware corporation, (the “Company”), pursuant to its 2014 Employment Commencement Incentive Plan, as amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”), an award of restricted stock |
|
| September 2, 2014 |
KYTH / Kythera Biopharma S-3 - - S-3 Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents As filed with the Securities and Exchange Commission on September 2, 2014 Registration No. |
|
| September 2, 2014 |
Statement Regarding the Computation of Ratios Exhibit 12.1 Statement Regarding the Computation of Ratios Our earnings are inadequate to cover combined fixed charges and preferred stock dividends. The following table sets forth the dollar amount of the coverage deficiency (in thousands) for the periods indicated. Six Months Ended Year Ended December 31, June 30, 2013 2012 2011 2010 2009 2014 EARNINGS: Net loss $ (51,911 ) $ (36,799 ) $ (11,152 |
|
| September 2, 2014 |
Exhibit 99.2 KYTHERA BIOPHARMACEUTICALS, INC. 2014 EMPLOYMENT COMMENCEMENT INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Kythera Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), pursuant to its 2014 Employment Commencement Incentive Plan (the “Plan”), hereby grants to the individual listed below (the “Optionee”), an option to purchase the number of shares of |
|
| September 2, 2014 |
Exhibit 25.1 File No. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE x CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-1486454 (I.R.S |
|
| September 2, 2014 |
KYTHERA Biopharmaceuticals, Inc. Dated as of , 20 Wilmington Trust, National Association Exhibit 4.3 KYTHERA Biopharmaceuticals, Inc. INDENTURE Dated as of , 20 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1 |
|
| August 11, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (C |
|
| August 11, 2014 |
Exhibit 99.1 KYTHERA Biopharmaceuticals Submits New Drug Submission to Health Canada for ATX-101 as First-in-Class Treatment for the Reduction of Submental Fat Westlake Village, Calif., Aug. 11, 2014 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced it submitted a New Drug Submission (NDS) to Health Canada seeking approval for the company’s investigational drug, ATX-101 (deoxycholi |
|
| August 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| August 7, 2014 |
Exhibit 99.1 PRESS RELEASE KYTHERA Biopharmaceuticals Releases Second Quarter 2014 Operating Results Westlake Village, Calif., August 7, 2014 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its second quarter 2014 and provided an update on recent accomplishments. “We made significant progress during the second quarter, including the submission of our New Drug |
|
| July 11, 2014 |
KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Application Exhibit 99.1 PRESS RELEASE KYTHERA Biopharmaceuticals Announces FDA Acceptance of ATX-101 New Drug Application Calabasas, Calif., July 10, 2014 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its New Drug Application (NDA) for ATX-101 (deoxycholic acid) has been accepted for filing by the U.S. Food and Drug Administration (FDA). The acceptance of the NDA reflects the FDA’s d |
|
| July 11, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Com |
|
| June 9, 2014 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Comm |
|
| May 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Comm |
|
| May 8, 2014 |
KYTHERA Biopharmaceuticals Releases First Quarter 2014 Operating Results Exhibit 99.1 PRESS RELEASE KYTHERA Biopharmaceuticals Releases First Quarter 2014 Operating Results Calabasas, Calif., May 8, 2014 KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its first quarter 2014, and provided an update on recent accomplishments. We made significant progress in the first quarter and we remain on track to file our New Drug Application w |
|
| May 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 8, 2014 |
ASSIGNMENT AND NOVATION AGREEMENT BAYER CONSUMER CARE AG KYTHERA HOLDINGS LTD. Exhibit 10.3 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. ASSIGNMENT AND NOVATION AGREEMENT BETWEEN BAYER CONSUMER CARE AG AND KYTHERA HOLDINGS LTD. ASSIGNMENT AND NOVATION AGREEMENT THIS ASSIGNMENT AND NOVATION AGREEMENT (this ?Agreement?), |
|
| May 8, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Commi |
|
| May 8, 2014 |
RESTRUCTURING AGREEMENT BAYER CONSUMER CARE AG KYTHERA BIOPHARMACEUTICALS, INC. Exhibit 10.2 RESTRUCTURING AGREEMENT BETWEEN BAYER CONSUMER CARE AG AND KYTHERA BIOPHARMACEUTICALS, INC. RESTRUCTURING AGREEMENT THIS RESTRUCTURING AGREEMENT (this ?Restructuring Agreement?), is entered into as of March 7, 2014 (the ?Effective Date?), by and among Bayer Consumer Care AG, a company organized under the laws of Switzerland (?Bayer?) and KYTHERA Biopharmaceuticals, Inc., a Delaware co |
|
| April 17, 2014 |
DEF 14A 1 a2219689zdef14a.htm DEF 14A Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box |
|
| April 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin |
|
| March 31, 2014 |
Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (C |
|
| March 21, 2014 |
As filed with the Securities and Exchange Commission on March 21, 2014 Registration No. |
|
| March 17, 2014 |
FIFTH AMENDMENT TO OFICE LEASE Exhibit 10.4(f) FIFTH AMENDMENT TO OFICE LEASE THIS FIFTH AMENDMENT TO OFFICE LEASE (this ?Amendment?) is entered into as of the 29 day of January 2014 by and between 27200 Associates, LLC, a California limited liability company (?Lessor?), and Kythera Biopharmaceuticals, Inc., a Delaware corporation, (?Lessee?). WITNESSETH WHEREAS, Lessor and Lessee, entered into that certain Standard Multi-Lesse |
|
| March 17, 2014 |
List of Subsidiaries of KYTHERA Biopharmaceuticals, Inc. QuickLinks - Click here to rapidly navigate through this document Exhibit 21.1 List of Subsidiaries of KYTHERA Biopharmaceuticals, Inc. Jurisdiction of Incorporation or Organization Kythera Biopharmaceuticals (Europe) Ltd. United Kingdom Kythera Biopharmaceuticals Australia Pty. Ltd. Australia Kythera Holdings Ltd. Bermuda QuickLinks Exhibit 21.1 List of Subsidiaries of KYTHERA Biopharmaceuticals, |
|
| March 17, 2014 |
Exhibit 10.20 OFFICE LEASE (30930 RUSSELL RANCH ROAD) BETWEEN RUSSELL RANCH ROAD, LLC, a Delaware limited liability company AS LANDLORD AND KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation AS TENANT OFFICE LEASE (30930 RUSSELL RANCH ROAD) THIS OFFICE LEASE (this “Lease”) is made and entered into as of March 12, 2014 (the “Effective Date”), by and between “Landlord” RUSSELL RANCH ROAD, LLC, |
|
| March 17, 2014 |
KYTHERA BIOPHARMACEUTICALS ANNOUNCES 2013 OPERATING RESULTS Exhibit 99.1 PRESS RELEASE KYTHERA BIOPHARMACEUTICALS ANNOUNCES 2013 OPERATING RESULTS Calabasas, Calif., March 17 2014 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its quarter and year ended December 31, 2013, and provided an update on recent accomplishments. “2013 was a productive year for KYTHERA. Most notably, we announced positive results from our piv |
|
| March 17, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| March 17, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Use these links to rapidly review the document TABLE OF CONTENTS ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk. KYTHERA BIOPHARMACEUTICALS, INC. Index to Financial Statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For t |
|
| March 10, 2014 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 7, 2014, by and between KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), KYTHERA Holdings Ltd., a company incorporated under the laws of Bermuda (“KHL”) and Bayer Consumer Care AG, a company organized under the laws of Switzerland (“Bayer”). RECITALS A. The |
|
| March 10, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2014 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Com |
|
| March 10, 2014 |
Exhibit 4.1 NOTE $51,000,000.00 March 7, 2014 FOR VALUE RECEIVED, KYTHERA BIOPHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), located at 27200 West Agoura Road, Suite 200, Calabasas, CA 91301, promises to pay to the order of KYTHERA HOLDINGS LTD., a wholly-owned subsidiary of Borrower and a company incorporated under the laws of Bermuda (“Lender”), the principal amount of Fifty One Mill |
|
| March 10, 2014 |
Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 7, 2014, by and between KYTHERA Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Bayer Consumer Care AG, a company organized under the laws of Switzerland (the “Investor”). This Agreement is made pursuant to the Securities Purchase Agreement, dat |
|
| February 14, 2014 |
KYTH / Kythera Biopharma / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 2 )* Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2013 Date of Event W |
|
| February 10, 2014 |
EX-A Exhibit A CUSIP No. 501570 10 5 13G AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of KYTHERA Biopharmaceuticals, Inc. Dated: February 7, 2014 |
|
| February 10, 2014 |
KYTH / Kythera Biopharma / Prospect Venture Partners III L P - SC 13G/A Passive Investment SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 7, 2014 |
Identification and Classification of the Subsidiary Which Acquired the Security EXHIBIT 2 Waddell & Reed Investment Management Company - Tax ID No. 48-1106973 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 Ivy Investment Management Company - Tax ID No. 03-0481447 Investment Advisor registered under Section 203 of the Investment Advisors Act of 1940 |
|
| February 7, 2014 |
Kythera Biopharmaceuticals, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 7, 2014 |
Power of Attorney EXHIBIT 3 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, THAT: The undersigned, Waddell & Reed Financial, Inc. |
|
| February 7, 2014 |
EX-1 2 d662990dex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT Waddell & Reed Financial, Inc., Waddell & Reed Financial Services, Inc., Waddell & Reed, Inc., Waddell & Reed Investment Management Company and Ivy Investment Management Company (the “Filing Persons”), hereby agree to file jointly a Schedule 13G and any amendments thereto relating to the aggregate ownership by each of t |
|
| February 6, 2014 |
KYTH / Kythera Biopharma / ARCH VENTURE FUND VI LP - KYTHERA BIOPHARMACEUTICALS Passive Investment SC 13G/A 1 kythera-sch13g17609.htm KYTHERA BIOPHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2013 (Date of Event which Requires Filing of this Statement) |
|
| February 5, 2014 |
KYTH / Kythera Biopharma / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G 1 kbio.htm DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: KYTHERA BIOPHARMACEUTICALS INC Title of Class of Securities: Common Stock CUSIP Number: 501570105 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b |
|
| November 14, 2013 |
KYTHERA Biopharmaceuticals Announces Third Quarter 2013 Operating Results EX-99.1 2 a13-243121ex99d1.htm EX-99.1 Exhibit 99.1 PRESS RELEASE KYTHERA Biopharmaceuticals Announces Third Quarter 2013 Operating Results LOS ANGELES, November 14, 2013 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its third quarter 2013, and provided an update on recent accomplishments. Summary Financial Results Cash and cash equivalents, marketable secu |
|
| November 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 14, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| October 9, 2013 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| October 8, 2013 |
QuickLinks - Click here to rapidly navigate through this document As filed with the Securities and Exchange Commission on October 8, 2013 Registration No. |
|
| October 7, 2013 |
Exhibit 1.1 UNDERWRITING AGREEMENT KYTHERA Biopharmaceuticals, Inc. Shares of Common Stock Underwriting Agreement , 2013 J.P. Morgan Securities LLC Merrill Lynch, Pierce, Fenner & Smith Incorporated Leerink Swann LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Merrill Lynch, Pierce, Fenner |
|
| October 7, 2013 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| October 7, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (C |
|
| September 30, 2013 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| September 27, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commi |
|
| September 27, 2013 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commis |
|
| September 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A Amendment No. 1 Use these links to rapidly review the document TABLE OF CONTENTS PART IV Index to Financial Statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| September 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| September 19, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 17, 2013 Date of Report (date of earliest event reported) KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of (Commission Fil |
|
| September 19, 2013 |
Exhibit 99.1 Investor Contact: Heather Rowe Associate Director, Investor Relations Tel: (818) 587- 4559 [email protected] PRESS RELEASE KYTHERA Appoints F. Michael Ball to Board of Directors Hospira Chief Executive Officer and Former Allergan President Brings Extensive Healthcare and Aesthetics Experience Calabasas, Calif., September 19, 2013 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KY |
|
| September 17, 2013 |
The beauty of science. September 17, 2013 Exhibit 99.1 The beauty of science. September 17, 2013 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “contemplate,” “believe,” “estimate,” “predict |
|
| September 17, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 16, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| September 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| September 9, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| August 6, 2013 |
KYTHERA Biopharmaceuticals Announces Second Quarter 2013 Operating Results Exhibit 99.1 Contact: Heather Rowe Associate Director, Investor Relations Tel: (818) 587- 4559 [email protected] PRESS RELEASE KYTHERA Biopharmaceuticals Announces Second Quarter 2013 Operating Results LOS ANGELES, August 6, 2013 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its second quarter 2013, and provided an update on recent accomplishments. |
|
| August 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| August 6, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00 |
|
| June 7, 2013 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Comm |
|
| May 13, 2013 |
Exhibit 10.4 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. COMMERCIAL DEVELOPMENT AND SUPPLY AGREEMENT BY AND BETWEEN KYTHERA BIOPHARMACEUTICALS, INC. AND CAMBRIDGE MAJOR LABORATORIES, INC. COMMERCIAL DEVELOPMENT AND SUPPLY AGREEMENT This C |
|
| May 13, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0 |
|
| May 13, 2013 |
FOURTH AMENDMENT TO OFFICE LEASE Exhibit 10.5 FOURTH AMENDMENT TO OFFICE LEASE THIS FOURTH AMENDMENT TO OFFICE LEASE (this ?Amendment?) is entered into as of the 28th day of March 2013 by and between 27200 Associates, LLC, a California limited liability company (?Lessor?), and Kythera Biopharmaceuticals, Inc., a Delaware corporation (?Lessee?). WITNESSETH: WHEREAS, Lessor and Lessee, entered into that certain Standard Multi-Lesse |
|
| May 13, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Comm |
|
| May 13, 2013 |
KYTHERA Biopharmaceuticals Announces First Quarter 2013 Operating Results EX-99.1 2 a13-120931ex99d1.htm EX-99.1 Exhibit 99.1 Contact: Heather Rowe Associate Director, Investor Relations Tel: (818) 587- 4559 [email protected] PRESS RELEASE KYTHERA Biopharmaceuticals Announces First Quarter 2013 Operating Results LOS ANGELES, May 13, 2013 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its first quarter 2013, and provided a |
|
| April 26, 2013 |
Use these links to rapidly review the document TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 25, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| April 5, 2013 |
Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Com |
|
| April 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| April 2, 2013 |
SEPARATION AGREEMENT AND RELEASE Exhibit 10.1 SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release (“Agreement”) is made by and between Patricia Walker, M.D., Ph.D. (“Employee”) and KYTHERA Biopharmaceuticals, Inc. (the “Company”) (collectively referred to as the “Parties” or individually referred to as a “Party”). RECITALS WHEREAS, Employee was employed by the Company; WHEREAS, Employee signed an Amended and Re |
|
| April 2, 2013 |
SENIOR ADVISOR TO THE BOARD OF DIRECTORS AGREEMENT Exhibit 10.2 SENIOR ADVISOR TO THE BOARD OF DIRECTORS AGREEMENT This Sr. Advisor to the Board of Directors Agreement (“Agreement”) is entered into as of March 28, 2013 (the “Effective Date”) by and between KYTHERA Biopharmaceuticals, Inc. (the “Company”) and Patricia Walker, MD, PhD (“Sr. Advisor”). The Company desires to retain Sr. Advisor as an independent contractor to perform consulting servic |
|
| March 26, 2013 |
As filed with the Securities and Exchange Commission on March 26, 2013 Registration No. |
|
| March 26, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K 10-K 1 a2213914z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS PART IV Index to Financial Statements Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PU |
|
| March 26, 2013 |
KYTHERA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT Exhibit 10.18 KYTHERA BIOPHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is entered into as of March 23, 2013 (the “Effective Date”) by and between Kythera Biopharmaceuticals, Inc. (the “Company”) and Frederick Beddingfield, III, MD, PhD (“Employee”). 1. Duties and Scope of Employment. (a) Positions and Duties. As of the Effective Date, Employee will serve as |
|
| March 21, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Co |
|
| March 21, 2013 |
KYTHERA BIOPHARMACEUTICALS ANNOUNCES 2012 OPERATING RESULTS EX-99.1 2 a13-81211ex99d1.htm EX-99.1 Exhibit 99.1 Contact: Heather Rowe Associate Director, Investor Relations Tel: (818) 587- 4559 [email protected] PRESS RELEASE KYTHERA BIOPHARMACEUTICALS ANNOUNCES 2012 OPERATING RESULTS LOS ANGELES, March 21, 2013 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for its quarter and year ended December 31, 2012. “2012 |
|
| March 12, 2013 |
Exhibit 99.1 Investor Contact: Heather Rowe Tel: (818) 587-4559 [email protected] MEDICAL AESTHETICS VETERAN FREDERICK BEDDINGFIELD, III, MD, PHD APPOINTED NEW CHIEF MEDICAL OFFICER OF KYTHERA BIOPHARMACEUTICALS LOS ANGELES, March 12, 2013 — KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a biotechnology company focused on the development and commercialization of prescription products in aest |
|
| March 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2013 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) (Com |
|
| February 14, 2013 |
KYTH / Kythera Biopharma / Partner Fund Management, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2012 Date of Event W |
|
| February 11, 2013 |
KYTH / Kythera Biopharma / Versant Affiliates Fund II-A, LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. )* Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570 10 5 (CUSIP Number) December 31, 2012 (Dat |
|
| February 8, 2013 |
KYTH / Kythera Biopharma / ARCH VENTURE FUND VI LP - KYTHERA BIOPHARMACEUTICALS Passive Investment SC 13G 1 kythera-sch13g17466.htm KYTHERA BIOPHARMACEUTICALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 501570105 (CUSIP Number) December 31, 2012 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| January 28, 2013 |
EX-99.1 2 d475324dex991.htm JOINT FILING STATEMENT CUSIP No. 501570 10 5 13G Exhibit A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of KYTHERA Bi |
|
| January 28, 2013 |
KYTH / Kythera Biopharma / Prospect Venture Partners III L P - SCHEDULE 13G Passive Investment Schedule 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| December 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2012 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| December 5, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2012 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| December 5, 2012 |
Exhibit 10.1 AMENDMENT NO. 03 Dated November 30, 2012 TO that certain Loan and Security Agreement No. 1991 dated as of March 21, 2011, as amended (“Agreement”), by and between LIGHTHOUSE CAPITAL PARTNERS VI, L.P. (“Lender”) and KYTHERA BIOPHARMACEUTICALS, INC. (“Borrower”). WHEREAS, Borrower and Lender have previously entered into the Agreement; WHEREAS, Borrower has requested that Lender modify c |
|
| December 3, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file num |
|
| November 13, 2012 |
KYTHERA BIOPHARMACEUTICALS ANNOUNCES THIRD QUARTER 2012 FINANCIAL RESULTS Exhibit 99.1 Investor & Media Contact: Heather Rowe Tel: (818) 587-4559 [email protected] KYTHERA BIOPHARMACEUTICALS ANNOUNCES THIRD QUARTER 2012 FINANCIAL RESULTS LOS ANGELES, November 13, 2012 – KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today reported financial results for the three and nine months ended September 30, 2012, and provided an update on recent accomplishments. “We hav |
|
| November 13, 2012 |
KYTHERA BIOPHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. EX-10.3(A) 2 a12-227401ex10d3a.htm EX-10.3(A) Exhibit 10.3(a) KYTHERA BIOPHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Kythera Biopharmaceuticals, Inc. 2012 Equity Incentive Award Plan (the “Plan”) is to promote the success and enhance the value of Kythera Biopharmaceuticals, Inc. (the “Company”) by linking the individual interests of the Employees, C |
|
| November 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe |
|
| November 13, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2012 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) |
|
| October 19, 2012 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Kythera Biopharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each |
|
| October 19, 2012 |
KYTH / Kythera Biopharma / Partner Fund Management, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Kythera Biopharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.00001 per share (Title of Class of Securities) 501570105 (CUSIP Number) October 11, 2012 Date of Event Whic |
|
| October 16, 2012 |
AMENDED AND RESTATED BYLAWS OF KYTHERA BIOPHARMACEUTICALS, INC. (a Delaware corporation) Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF KYTHERA BIOPHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROC |
|
| October 16, 2012 |
As filed with the Securities and Exchange Commission on October 16, 2012 Registration No. |
|
| October 16, 2012 |
KYTHERA BIOPHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. Exhibit 99.3 KYTHERA BIOPHARMACEUTICALS, INC. 2012 EQUITY INCENTIVE AWARD PLAN ARTICLE 1. PURPOSE The purpose of the Kythera Biopharmaceuticals, Inc. 2012 Equity Incentive Award Plan (the “Plan”) is to promote the success and enhance the value of Kythera Biopharmaceuticals, Inc. (the “Company”) by linking the individual interests of the Employees, Consultants and members of the Board to those of t |
|
| October 16, 2012 |
Exhibit 99.1 27200 West Agoura Road 818.587.4500 Phone Suite 200 818.587.4591 Fax Calabasas, CA 91301 Investor Contact: Heather Rowe Tel: (818) 587-4559 [email protected] KYTHERA BIOPHARMACEUTICALS ANNOUNCES CLOSING OF INITIAL PUBLIC OFFERING AND EXERCISE OF UNDERWRITERS’ OVER-ALLOTMENT OPTION LOS ANGELES, October 16, 2012 — KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced |
|
| October 16, 2012 |
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION KYTHERA BIOPHARMACEUTICALS, INC. Exhibit 3.1 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KYTHERA BIOPHARMACEUTICALS, INC. Keith Leonard and Keith Klein, hereby certifies that: ONE: The name of this corporation is Kythera Biopharmaceuticals, Inc. The corporation was incorporated on June 3, 2004 under the name Dermion, Inc. pursuant to the General Corporation Law of the State of Delaware (the “Delaware General Corp |
|
| October 16, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2012 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35663 03-0552903 (State or other jurisdiction of incorporation) ( |
|
| October 11, 2012 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| October 10, 2012 |
As filed with the Securities and Exchange Commission on October 10, 2012 Registration No. |
|
| October 9, 2012 |
SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KYTHERA BIOPHARMACEUTICALS, INC. Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KYTHERA BIOPHARMACEUTICALS, INC. Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The name of the Corporation is Kythera Biopharmaceuticals, Inc. The Corporation’s original Certificate of Incorporation was filed with the Secret |
|
| October 9, 2012 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| October 4, 2012 |
KYTHERA Biopharmaceuticals, Inc. 27200 West Agoura Road, Suite 200 Calabasas, CA 91301 October 4, 2012 VIA FACSIMILE AND EDGAR TRANSMISSION United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Riedler, Assistant Director Rose Zukin Daniel Greenspan Re: KYTHERA Biopharmaceuticals, Inc. Registration Statement |
|
| October 4, 2012 |
J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 Goldman, Sachs & Co. 200 West Street New York, NY 10282 October 4, 2012 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7010 Re: KYTHERA Biopharmaceuticals, Inc. Registration Statement on Form S-1 Registration File No. 333- 181476 Dear Ladies and Gentlemen: In accorda |
|
| September 24, 2012 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| September 24, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 KYTHERA BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 03-0552903 (State of incorporation or organization) (I.R.S. Employer Identification No.) 27200 West |
|
| September 24, 2012 |
SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION KYTHERA BIOPHARMACEUTICALS, INC. Exhibit 3.2 SEVENTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KYTHERA BIOPHARMACEUTICALS, INC. Keith Leonard and Keith Klein, hereby certifies that: ONE: The name of this corporation is Kythera Biopharmaceuticals, Inc. The corporation was incorporated on June 3, 2004 under the name Dermion, Inc. pursuant to the General Corporation Law of the State of Delaware (the “Delaware General Corp |
|
| September 24, 2012 |
SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KYTHERA BIOPHARMACEUTICALS, INC. EX-3.1(B) 2 a2211119zex-31b.htm EX-3.1(B) Exhibit 3.1(b) SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KYTHERA BIOPHARMACEUTICALS, INC. Kythera Biopharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), certifies that: A. The name of the Corporation is Kythera Biopharmaceuticals, Inc. The Corporation’s original Certifica |
|
| September 20, 2012 |
S-1/A 1 a2210175zs-1a.htm S-1/A#4 Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. Index to Financial Statements Table of Contents As filed with the Securities and Exchange Commission on September 20, 2012 Registration No. 333-181476 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STAT |
|
| September 20, 2012 |
September 19, 2012 File No. 048370-0008 VIA EDGAR AND HAND DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Riedler, Assistant Director Rose Zukin Daniel Greenspan Re: KYTHERA Biopharmaceuticals, Inc. Amendment No. 4 to Registration Statement on Form S-1 File No. 333-181476 Ladies and Gentlem |
|
| September 12, 2012 |
[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. |
|
| August 31, 2012 |
Exhibit 1.1 UNDERWRITING AGREEMENT KYTHERA Biopharmaceuticals, Inc. [·] Shares of Common Stock Underwriting Agreement [·] , 2012 J. P. Morgan Securities LLC Goldman, Sachs & Co. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J. P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman, Sachs & Co. 200 West Street New York, NY 10282 Ladies and |
|
| August 31, 2012 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| August 31, 2012 |
Exhibit 4.5(b) AMENDMENT NO. 01 Dated July 23, 2012 TO that certain Preferred Stock Warrant Agreement dated as of December 30, 2011, (the “Warrant”) by and between LIGHTHOUSE CAPITAL PARTNERS VI, L.P. (“Holder”) and KYTHERA BIOPHARMACEUTICALS, INC. (“Company”). (All capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Warrant.) Without limiting or amend |
|
| August 31, 2012 |
Exhibit 4.2 DELAWARE JUNE 2004 SEAL KYTHERA BIOPHARMACEUTICALS, INC. CORPORATE This certifies that is the record holder of Dated: KB INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $.00001 PAR VALUE, OF KYTHERA Biopharmaceuticals, Inc. transferable on the books of the corporation in person or by duly authorized attorney upon surrender of th |
|
| August 31, 2012 |
Exhibit 10.3(c) AMENDMENT NO. 02 Dated July 23, 2012 TO that certain Loan and Security Agreement No. 1991 dated as of March 21, 2011, (“Agreement”), by and between LIGHTHOUSE CAPITAL PARTNERS VI, L.P. (“Lender”) and KYTHERA BIOPHARMACEUTICALS, INC. (“Borrower”). WHEREAS, Borrower and Lender have previously entered into the Agreement; WHEREAS, Borrower has requested that Lender modify certain terms |
|
| July 11, 2012 |
Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. |
|
| July 11, 2012 |
July 11, 2012 File No. 048370-0008 VIA EDGAR AND HAND DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Riedler, Assistant Director Rose Zukin Daniel Greenspan Re: KYTHERA Biopharmaceuticals, Inc. Amendment No. 2 to Registration Statement on Form S-1 File No. 333-181476 Ladies and Gentleman: O |
|
| June 11, 2012 |
MANUFACTURING AND SUPPLY AGREEMENT Exhibit 10.8(a) [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. MANUFACTURING AND SUPPLY AGREEMENT THIS MANUFACTURING AND SUPPLY AGREEMENT dated as of July 7, 2009 (the “Effective Date”) is made by and between Pfizer Inc., a corporation organiz |
|
| June 11, 2012 |
First Amendment to Manufacturing and Supply Agreement Exhibit 10.8(b) [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. First Amendment to Manufacturing and Supply Agreement This First Amendment to the Manufacturing and Supply Agreement (this “Amendment”) is made as of the 21 of May, 2012 (the “Effe |
|
| June 11, 2012 |
June 11, 2012 File No. 048370-0008 VIA EDGAR AND HAND DELIVERY United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Jeffrey Riedler, Assistant Director Rose Zukin Daniel Greenspan Re: KYTHERA Biopharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 File No. 333-181476 Ladies and Gentleman: O |
|
| June 11, 2012 |
S-1/A 1 a2209812zs-1a.htm S-1/A Use these links to rapidly review the document Table of Contents KYTHERA BIOPHARMACEUTICALS, INC. Index to Financial Statements Table of Contents As filed with the Securities and Exchange Commission on June 11, 2012 Registration No. 333-181476 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT U |
|
| May 17, 2012 |
FIRST AMENDMENT TO LICENSE AGREEMENT Exhibit 10.5(b) [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. FIRST AMENDMENT TO LICENSE AGREEMENT This FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into as of March 21, 2011 (“First Amendment Effective Date”) by and be |
|
| May 17, 2012 |
KYTHERA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT Exhibit 10.12 KYTHERA BIOPHARMACEUTICALS, INC. AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (the “Agreement”) is entered into as of April 2, 2012 (the “Effective Date”) by and between Kythera Biopharmaceuticals, Inc. (the “Company”) and Keith Leonard (“Employee”), and amends and restates in its entirety that certain Employment Agreement (the “Prior Agree |
|
| May 17, 2012 |
QuickLinks - Click here to rapidly navigate through this document Exhibit 99.1 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Abu Dhabi Moscow Barcelona Munich Beijing New Jersey Boston New York Brussels Orange County Chicago Paris April 6, 2012 Doha Riyadh Dubai Rome Frankfurt San Diego Hamburg San Francisco Hong Kong Sha |
|
| May 17, 2012 |
SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT Exhibit 10.6(a) [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT THIS SERVICES, RESEARCH, DEVELOPMENT AND COLLABORATION AGREEMENT (this “Collaboration Agreement”) is entered into as of |
